NCT03456466View on ClinicalTrials.gov

Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

May 1, 2017

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2018

Conditions
Non-hodgkin's Lymphoma
Interventions
DRUG

TQB2303

375mg/m2 ，iv

DRUG

Rituximab

375mg/m2 ，iv

Trial Locations (2)

210009

RECRUITING

Jiangsu Cancer Hospital, Nanjing

215006

RECRUITING

First Affiliated Hospital of Suzhou University, Suzhou

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY

NCT03456466 - Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter